China Universal Asset Management Co. Ltd. Has $15.25 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• China Universal Asset Management cut its stake in Regeneron by 7.5% to 19,753 shares, holding about $15.25 million in the stock and making REGN its 19th largest position (≈1.2% of its portfolio).
• Company insiders have been selling recently — a total of 3,774 shares worth about $2.94 million were sold in the last 90 days (insiders now own 7.02% of the company), including notable sales by a director and an SVP.
• Regeneron has several positive catalysts — including the FDA approval of gene therapy Otarmeni, tariff relief under a White House agreement, a raised quarterly dividend to $0.94 ($3.76 annual), and a recent earnings beat — supporting analyst upgrades and a consensus "Moderate Buy" rating.

China Universal Asset Management Co. Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,753 shares of the biopharmaceutical company's stock after selling 1,606 shares during the period. Regeneron Pharmaceuticals comprises approximately 1.2% of China Universal Asset Management Co. Ltd.'s holdings, making the stock its 19th largest holding. China Universal Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $15,247,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Brighton Jones LLC increased its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $226,000. Arrowstreet Capital Limited Partnership acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $3,183,000. Gabelli Funds LLC grew its holdings in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company's stock worth $978,000 after acquiring an additional 55 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company's stock worth $16,985,000 after acquiring an additional 5,120 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,774 shares of company stock valued at $2,942,738. Company insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.6%

NASDAQ REGN opened at $766.02 on Friday. The stock has a fifty day moving average of $763.87 and a 200-day moving average of $729.93. The stock has a market capitalization of $80.98 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 1.66 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $12.07 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.2 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.05%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating on the stock in a report on Wednesday, April 8th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, April 11th. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. Finally, Oppenheimer reissued an "outperform" rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $818.13.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni, the first gene therapy to restore hearing — a clear pipeline win that validates Regeneron’s genetic‑medicine platform and de‑risks future revenue streams tied to novel products. Read More.
• Positive Sentiment: Regulatory and clinical data look strong — trial results cited high responder rates (e.g., CHORD trial outcomes reported), supporting commercial potential and positive sentiment around commercialization prospects. Read More.
• Positive Sentiment: Company secured tariff relief under the White House agreement (three years) — a near‑term margin/cost benefit that investors view favorably. Read More.
• Positive Sentiment: Analyst support/upgrades — TD Cowen raised its price target (to $960) and Cantor Fitzgerald reaffirmed “overweight,” reinforcing buy-side conviction and likely contributing to demand. Read More.
• Positive Sentiment: Dupixent label expansions (U.S./EU pediatric approvals) add incremental, low‑risk revenue upside and diversify near‑term growth drivers beyond gene therapy. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major PR/ access move that increases goodwill and access but reduces near‑term product revenue in the U.S.; it may help uptake and market positioning internationally. Read More.
• Negative Sentiment: The agreement includes offering prescriptions at “most‑favored‑nation” prices for some Americans — this could compress pricing and long‑run revenue/margins if broadly applied. Read More.
• Negative Sentiment: Sector weakness: broader health‑care stocks were lower in afternoon trading, which can cap upside even with company‑specific news. Read More.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.